Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Bernard Jackman believes IRFU high-performance director David Humphreys has a major job on his hands to address the player pathway system in the country that has failed to widen the playing pool.

A study published in Nature Medicine identified a link between the placebo effect and immune system function. In the experiment, individuals who generated positive expectations showed a stronger ...

Mr. Shinners is a pianist and harpsichordist and hosts the podcast “W.T.F. Bach.” Classical music has been in a crisis for decades. New generations don’t seem to care about it. The institutions that ...

Performances in N.Y.C. Advertisement Supported by Recent works by Gabriela Ortiz, choral music by David Lang and unreleased recordings by Radu Lupu are among our selections. Los Angeles Philharmonic; ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Lots of people are excited about the idea of using plants to help us draw down some of the excess carbon dioxide we’ve been pumping into the atmosphere. It would be nice to think that we could ...

He sits squarely in front of us on the screen, a full-bodied man with a carefully trimmed white beard and a nearly bald head, his eyes looming behind dark-framed glasses—one eye glaring with cyclopean ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...